UCB Bought Neurona for $650M, Up to $1.15B Total

UCB paid $650 million in cash for Neurona Therapeutics, with up to $500 million in milestones pushing the total deal ceiling to $1.15 billion. The deal closes by end of Q2.

What UCB gets: NRTX-1001, a neuronal cell therapy in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy. It’s a single dose administered directly into the brain, designed to introduce GABA-producing cells intended to repair overactive neural networks in mTLE patients.

This is the second time UCB has bought into epilepsy this decade. In 2022, the Belgian pharma bought Zogenix for up to $1.9 billion and walked away with Fintepla, which generated 427 million euros in sales last year and is approaching a potential label expansion into a third epileptic disorder. By that measure, UCB knows how to turn epilepsy acquisitions into revenue.

The Neurona deal marks what UCB called “a strategic expansion into regenerative medicine and advanced therapies,” a step beyond its core established epilepsy franchise. CEO Jean-Christophe Tellier described NRTX-1001 as potentially offering “durable targeted repair of the nervous system following a single dose.” One-and-done cell therapies don’t come cheap; UCB’s willingness to go to $1.15 billion for a Phase I/II asset reflects that.

The deal dropped into a busy M&A window: the second half of March alone logged roughly $30 billion in deal activity across biopharma, with Neurocrine and Eli Lilly among the recent buyers.

The question is whether a Phase I/II asset justifies the $650 million floor, let alone the full milestone stack.

Diana Kowalski